Table 3.
Bivariable and multivariable results from the logistic regression analysis regarding sarcopenia status (n = 132)
| Unadjusted | Adjusted | |||
|---|---|---|---|---|
| OR (95% CI) | p-value | OR (95% CI) | p-value | |
| Statin | ||||
| No | 1 | 1 | ||
| Yes | 0.39 (0.16, 0.96) | 0.040 | 0.03 (0.01, 0.30) | 0.003 |
| Age, years | 1.04 (0.99, 1.08) | 0.077 | 1.09 (1.01, 1.17) | 0.022 |
| Sex | ||||
| Women | 1 | 1 | ||
| Men | 0.04 (0.01, 0.14) | < 0.001 | 0.01 (0.00, 0.07) | < 0.001 |
| LVEF categories | ||||
| HFpEF | 1 | 1 | ||
| HFmrEF | 2.14 (0.66, 6.93) | 0.203 | 5.07 (0.61, 42.14) | 0.133 |
| HFrEF | 2.40 (0.86, 6.73) | 0.096 | 3.78 (0.60, 25.07) | 0.169 |
| NYHA functional classes | ||||
| NYHA Class I | 1 | 1 | ||
| NYHA Class II | 2.74 (0.92, 8.12) | 0.068 | 4.82 (0.41, 56.56) | 0.211 |
| NYHA Class III | 2.10 (0.50, 8.82) | 0.311 | 14.65 (0.73, 293.72) | 0.079 |
| HF aetiology | ||||
| Ischaemic | 1 | 1 | ||
| Others | 1.63 (0.56, 4.73) | 0.368 | 1.30 (0.20, 8.40) | 0.781 |
| Polypharmacy | ||||
| < 5 medicines/day | 1 | 1 | ||
| ≥ 5 medicines/day | 2.99 (0.85, 10.72) | 0.093 | 26.87 (2.01, 359.26) | 0.013 |
| Physical activity | ||||
| Inactive | 1 | 1 | ||
| Minimally active + active | 0.25 (0.09, 0.70) | 0.009 | 0.09 (0.01, 0.65) | 0.017 |
| Body mass index, Kg.m−2 | 0.92 (0.82, 1.02) | 0.124 | 0.79 (0.65, 0.96) | 0.017 |
| Total fat intake, g/Kg/day | 0.72 (0.26, 2.04) | 0.538 | 0.34 (0.02, 5.20) | 0.437 |
Values are expressed in Odds Ratio (OR) and 95% Confidence Intervals (95% CI). HF = Heart Failure; LVEF = Left Ventricular Ejection Fraction; HFrEF = Heart Failure with reduced Ejection Fraction; HFmrEF = Heart Failure with mildly reduced Ejection Fraction; HFpEF = Heart Failure with preserved Ejection Fraction. Omnibus test: p < 0.001; Nagelkerke R-square = 0.706; Hosmer and Lemeshow test: p = 0.801. Model sensitivity: 76.0%; Model specificity: 95.3%. Model accuracy: 91.7%